曲美布汀

Name: 曲美布汀
Brand: 济南圣和化工有限公司

CAS 39133-31-8C22H29NO5MW 387.5

曲美布汀（CAS 39133-31-8）属医药中间体及原料药类产品，分子式 C22H29NO5，分子量 387.5。济南圣和化工有限公司常年现货供应该产品，常规纯度按批次COA提供(不公开发布)，可按客户需求安排分装包装，欢迎邮件或来电询价。

产品概览

CAS号	39133-31-8
分子式	C22H29NO5
分子量	387.5
熔点	78-82
LogP	4
纯度	按批次COA提供(不公开发布)
包装	按订单/批次确认(不公开发布)
应用领域	医药中间体及原料药
类别	医药中间体及原料药

应用领域

医药中间体及原料药

曲美布汀主要应用于医药中间体及原料药。具体使用工况下的添加量与规格要求，欢迎与技术团队沟通确认。

包装与储存

包装规格按订单/批次确认(不公开发布)

纯度规格按批次COA提供(不公开发布)

储存条件密封、阴凉干燥处保存

运输常规化工运输

样品可协商提供

交期现货/按订单安排

供货能力：曲美布汀备有现货，包装形式为按订单/批次确认(不公开发布)。我们支持对公转账并开具增值税发票，山东省内可安排快速配送，省外按物流时效发货，具体请联系 info@591daili.com。

质量与文件

每批产品随货提供 COA（分析证书）；可按需提供 MSDS/技术数据表及第三方检测报告。纯度与包装以批次 COA 及订单确认为准。

关于供应商

作为化工原料供应服务商，济南圣和化工有限公司长期服务于化工贸易、食品添加、医药中间体、日化原料等行业的采购需求。除曲美布汀外，您还可以在站内按 CAS 号或产品分类检索更多品类，获取规格与报价。

常见问题

曲美布汀的 CAS 号是多少？

曲美布汀的 CAS 号为 39133-31-8。

该产品的纯度和包装规格是什么？

常规纯度规格为按批次COA提供(不公开发布)，包装为按订单/批次确认(不公开发布)，随货提供 COA。

曲美布汀有什么用途？

主要应用于医药中间体及原料药。

如何购买或获取报价？

请发送邮件至 info@591daili.com 或通过 WhatsApp 联系，注明产品名称、CAS 号与需求数量，一个工作日内回复报价。供应商：济南圣和化工有限公司。

PubChem 公开数据

Description

Trimebutine · CAS 39133-31-8 · C22H29NO5. UNII QZ1OJ92E5R. Melting Point: 78-82.

Identification

CAS Registry Number	39133-31-8
PubChem CID	5573
Molecular formula	C22H29NO5
IUPAC name	[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
UNII (FDA)	QZ1OJ92E5R

Computed Descriptors

Molecular Weight	387.5
XLogP3	4
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	10
Exact Mass	387.20457303
Monoisotopic Mass	387.20457303
Topological Polar Surface Area	57.2
Heavy Atom Count	28
Formal Charge	0

Physical & Chemical Properties

Melting Point	78-82

Physical description & handling notes

Insoluble
191.12 Å² [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
177.75 Å² [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
197.43 Å² [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
193.19 Å² [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Regulatory Status

GHS notification summary	61.5% (8 / 13)

GHS Hazard Classification

GHS notification summary	61.5% (8 / 13)
Reported hazard statements	H302 (23.1%), H312 (30.8%), H332 (30.8%), H413 (15.4%)

This chemical does not meet GHS hazard criteria for 61.5% (8 of 13) of all reports.

H302 (23.1%): Harmful if swallowed [Warning Acute toxicity, oral]

Documented Uses

Indicated for symptomatic treatment of irritable bowel syndrome (IBS) and treatment of postoperative paralytic ileus following abdominal surgery.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03A - Drugs for functional gastrointestinal disorders

Synonyms

trimebutine; 39133-31-8; 2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate; Trimebutina; Trimebutinum; QZ1OJ92E5R; 2-Dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoat; DTXSID4023707; Transacalm; Modulon; (+-)-Trimebutine; Maleate, Trimebutine; RefChem:389346; Maleate Salt, Trimebutine; Salt, Trimebutine Maleate; DTXCID503707

Frequently Asked Questions

What are the CAS number and molecular formula of Trimebutine?

CAS 39133-31-8; molecular formula C22H29NO5; molecular weight — g/mol.

What other names is Trimebutine known by?

trimebutine, 39133-31-8, 2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate, Trimebutina, Trimebutinum, QZ1OJ92E5R.

Is Trimebutine classified as hazardous?

61.5% of GHS notifications report no hazard classification (8 of 13).

What are the key physical properties of Trimebutine?

Melting Point: 78-82.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.